<DOC>
	<DOCNO>NCT02006121</DOCNO>
	<brief_summary>The main purpose study investigate efficacy apomorphine subcutaneous infusion compare placebo advance Parkinson 's Disease patient . The secondary purpose study investigate safety tolerability apomorphine subcutaneous therapy .</brief_summary>
	<brief_title>Clinical Trial Apomorphine Subcutaneous Infusion Patients With Advanced Parkinson 's Disease</brief_title>
	<detailed_description>- Primary efficacy variable absolute change time spend `` OFF '' baseline end 12 week treatment period base patient diary Secondary Endpoints : - Percentage patient response therapy , define OFF time reduction least 2 hour , baseline end 12 week treatment period - Patient Global Impression Change - Absolute Change time spend `` ON without troublesome dyskinesia '' - Change oral L-dopa L-dopa equivalent dose - Change Unified Parkinson 's Disease Rating Scale ( UPDRS Part III motor examination ) ON period - Change Quality Life ( use PDQ-8 )</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Apomorphine</mesh_term>
	<criteria>Male female patient age ≥30 Diagnosis idiopathic Parkinson 's disease &gt; 3 year ' duration , define UK Brain Bank criterion ( exception &gt; 1 affected relative allow ) , without know suspected cause Parkinsonism Hoehn &amp; Yahr stage 3 ON 2 5 OFF state Motor fluctuation adequately control medical treatment include Ldopa judge optimal treat physician Average OFF time &gt; = 3 h/day base screen baseline diary entry day &lt; 2 hour OFF time record Stable medication regimen , stable dose Ldopa administer least 4 intake , least 28 day prior baseline . All oral transdermal antiparkinsonian drug permit , exception budipine . This regimen may include use Ldopa /DDCI rescue medication occur 2 time day , dose 200 mg Ldopa/day Patients must able differentiate ON OFF state troublesome nontroublesome dyskinesia Male female patient must compliant highly effective contraceptive method ( oral hormonal contraception alone consider highly effective must use combination barrier method ) study 9 month longterm followup period , sexually active Females childbearing potential must negative serum hCG pregnancy test screen Ability accurately complete paper diary designate day ( assistance caregiver , require ) , record period `` ON without troublesome dyskinesia '' , `` ON troublesome dyskinesia '' , OFF , sleep Written informed consent prior enrolment , provide detailed information nature , risk , scope clinical trial well expect desirable adverse effect study treatment Patients consider reliable capable adhere protocol , visit schedule , medication intake accord judgment investigator High suspicion parkinsonian syndrome Presence severe freeze clinically relevant postural instability lead fall ON state Concomitant therapy within 28 day prior baseline : apomorphine pen injection , alphamethyl dopa , metoclopramide , reserpine , neuroleptic , methylphenidate , amphetamine ; intrajejunal Ldopa Previous use apomorphine pump treatment History deep brain stimulation lesional surgery PD Any medical condition likely interfere adequate participation study , include e.g . current diagnosis unstable epilepsy ; clinically relevant cardiac dysfunction and/or myocardial infarction stroke within last 12 month Symptomatic , clinically relevant medically uncontrolled orthostatic hypotension Patients borderline QT interval correct heart rate accord Bazett 's formula ( QTc ) &gt; 450 m male &gt; 470 ms female Screening history long QT syndrome ; &gt; 450 m absolute duration Clinically relevant hepatic dysfunction ( total bilirubin &gt; 2.0 mg/dL , ALT AST &gt; 2 time upper limit normal ) Clinically relevant renal dysfunction ( serum creatinine &gt; 2.0 mg/dL ) ; Pregnant breastfeed woman Clinically relevant cognitive decline , define MMSE ≤24 accord DSM IV criterion dementia Active psychosis history least moderate psychosis past year , medically uncontrolled severe depression ; mild illusion hallucination sense `` feelings passage presence '' fully retain insight exclusion criterion Known history melanoma Any investigational therapy 4 week prior randomization History current drug alcohol abuse dependency</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>motor fluctuation</keyword>
	<keyword>well control</keyword>
	<keyword>medical treatment</keyword>
</DOC>